Compare TNXP & OSUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNXP | OSUR |
|---|---|---|
| Founded | 2007 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 198.6M | 214.1M |
| IPO Year | 2008 | 2000 |
| Metric | TNXP | OSUR |
|---|---|---|
| Price | $12.74 | $3.05 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | ★ 382.0K | 314.1K |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 91.75 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $13,107,000.00 | ★ $167,064,000.00 |
| Revenue This Year | $558.11 | $4.48 |
| Revenue Next Year | $38.29 | $7.76 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 29.85 | N/A |
| 52 Week Low | $11.60 | $2.08 |
| 52 Week High | $69.65 | $3.76 |
| Indicator | TNXP | OSUR |
|---|---|---|
| Relative Strength Index (RSI) | 43.00 | 45.27 |
| Support Level | $11.90 | $2.87 |
| Resistance Level | $14.52 | $3.25 |
| Average True Range (ATR) | 0.76 | 0.11 |
| MACD | -0.05 | -0.02 |
| Stochastic Oscillator | 22.75 | 25.35 |
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
OraSure Technologies Inc is a medical devices company that develops, manufactures, and distributes oral fluid diagnostic and collection devices. Its reportable segments are diagnostics and molecular solutions. The diagnostics segment produces rapid oral diagnostic tests and specimen collection devices for infectious diseases such as HIV and HCV. The molecular solutions segment specializes in kits used to collect, stabilize, and transport genetic material samples for molecular testing of both hereditary diseases and infectious diseases, such as COVID-19. The company gets majority of its sales from the molecular solutions business, derived mainly from customers in the United States.